George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.704%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 137.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on results of Placing and issue of equity

23 Apr 2020 13:00

RNS Number : 6817K
Faron Pharmaceuticals Oy
23 April 2020
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

Faron Pharmaceuticals Oy

 

Update on results of Placing

and

Issue of Equity

  

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 4.45 p.m. BST/ 6.45 p.m. EEST on 21 April 2020 regarding the proposed placing of new ordinary shares in the Company (the "Launch Notice") and the subsequent announcement released at 7.00 a.m. BST/ 9.00 a.m. EEST on 22 April 2020 ("Result Announcement"), unless the context provides otherwise.

 

Company announcement, 23 April 2020 at 1.00 p.m. BST/ 3.00 p.m. EEST

 

TURKU - FINLAND- Faron Pharmaceuticals Oy ("Faron" or the "Company") (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, is pleased to announce that following the Launch Notice and the Result Announcement, the proposed UK Placing has been subscribed for in full, in satisfaction of the UK Placee Condition. As a consequence, and conditional on, amongst other things, issue and registration of the Placing Shares, the Company has raised gross proceeds of approximately 14 million (£12.18 million) through the Placing.

 

The First Issue Shares (comprising 1,892,763 Placing Shares) are expected to be registered with the Finnish Trade Register today, 23 April 2020, and First Admission is expected to occur tomorrow as set out in the Result Announcement. The expected timing for issue, registration and admission to trading of the Second Issue Shares (comprising 950,000 Placing Shares) and the Third Issue Shares (comprising 657,237 Placing Shares) currently remains as set out in the Result Announcement.

 

 

Faron's enlarged issued number of shares immediately following registration of the First Issue Shares will be 45,183,510 Ordinary Shares with voting rights attached. The Company has no shares in Treasury; therefore upon, and subject to, registration of the First Issue Shares, the total number of voting rights in Faron will be 45,183,510 (the "Enlarged Number of Shares and Votes"). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Enlarged Number of Shares and Votes of the Company. Faron's enlarged issued number of shares immediately following registration of the Second Issue Shares will be 46,133,510 Ordinary Shares with voting rights attached. Faron's enlarged issued number of shares immediately following registration of the Third Issue Shares will be 46,790,747 Ordinary Shares with voting rights attached.

Exchange rate

Unless otherwise specified, this notice contains certain translations of euros into amounts in pounds sterling for the convenience of the reader based on the exchange rate of €1 = £0.87, being the published exchange rate by the European Central Bank at the close of business on 20 April 2020 (the latest practicable date prior to the date of the Launch Notice) rounded to 2 decimal places.

 

For more information please contact:

 

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com 

 

Carnegie Investment Bank AB, Financial Adviser

Mika Karikoski (Corporate Finance)

Phone: +358 40 741 6959

 

Panmure Gordon (UK) Limited, Nomad and Broker

Emma Earl, Freddy Crossley (Corporate Finance)

James Stearns (Corporate Broking)

Phone: +44 207 886 2892 

 

Consilium Strategic Communications

Mary-Jane Elliott

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 40 555 4727

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLFVLSIIVFII
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Warrants to IPF Funding Update
26th Mar 202410:00 amRNSFaron´s Annual Report 2023
18th Mar 20247:00 amRNSAdditional Positive Data from Phase 1 of BEXMAB
14th Mar 20247:00 amRNSFaron to Host BEXMAB Webcast
13th Mar 20242:00 pmRNSNotice of Annual General Meeting 2024
13th Mar 20247:00 amRNSFinancial Statement January 1 to December 31 2023
4th Mar 20247:00 amRNSBinding commitments for convertible loans
28th Feb 20244:00 pmRNSReplacement - Update to 2024 Financial Calendar
27th Feb 20246:00 pmRNSUpdate to Faron’s Financial Calendar for 2024
21st Feb 20242:00 pmRNSContinued Negotiations Regarding Events of Default
19th Feb 202410:30 amRNSEvents of Default
31st Jan 20247:00 amRNSFurther re: Exercise of options
25th Jan 20247:00 amRNSBEXMAB Insights into Patient Profiles
19th Jan 20241:00 pmRNSExercise of options - Issue of equity
9th Jan 20247:00 amRNSFirst Patient Dosed in Ph 2 of the BEXMAB Trial
3rd Jan 20247:00 amRNSPresentation at J.P. Morgan Healthcare Conference
22nd Dec 20237:00 amRNSFaron’s Financial Calendar for 2024
11th Dec 20237:00 amRNSPhase 1 BEXMAB data presented at ASH
7th Dec 20237:00 amRNSMATINS Trial in Cell Reports Medicine
4th Dec 20237:00 amRNSGrant of options
6th Nov 20238:13 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
6th Nov 20237:00 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
2nd Nov 20231:00 pmRNSFaron to present data from BEXMAB study at ASH
27th Oct 20231:00 pmRNSManager's transactions
27th Oct 20237:15 amRNSExercise of options
27th Oct 20237:00 amRNSResults of Placing
26th Oct 20234:30 pmRNSProposed Issue and Placing
11th Oct 20237:00 amRNSFaron Announces Positive BEXMAB Study Update
3rd Oct 20237:00 amRNSFaron to host webcast on new BEXMAB study data
22nd Sep 20234:00 pmRNSBoard Changes
22nd Sep 202311:00 amRNSResults of EGM
21st Sep 20237:00 amRNSFaron Appoints Interim Chief Medical Officer
8th Sep 20237:00 amRNSChange in the Board of Directors
6th Sep 20237:00 amRNSFaron to Present at H.C. Wainwright Conference
1st Sep 202310:00 amRNSNotice of EGM
31st Aug 20232:00 pmRNSExercise of options
29th Aug 20237:01 amRNSFaron 2023 Half-Year Financial Results
29th Aug 20237:00 amRNSFDA Orphan Drug Designation for Bexmarilimab
4th Aug 20237:00 amRNSNotice of Half-Year Financial Results
2nd Aug 20237:00 amRNSFaron to Participate at Canaccord Conference
25th Jul 20237:00 amRNSGrant of Options
19th Jul 20237:01 amRNSFaron to Hold BEXMAB Study Conference Call
19th Jul 20237:00 amRNSBEXMAB study update
30th Jun 20234:52 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSAnnouncement of Placing
12th Jun 20237:00 amRNSExercise of options
9th Jun 20238:00 amRNSNew biomarker data from BEXMAB study at EHA2023
5th Jun 20237:00 amRNSBoard Member to Assume Transactional Advisor Role
24th Apr 20237:00 amRNSBexmarilimab Efficacy and Safety in MATINS Trial
19th Apr 20237:00 amRNSBexmarilimab KOL Event

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.